Why is the ResMed share price down 4.9% today?

Investors seem to have changed their minds on Resmed over the weekend.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • ResMed Inc (ASX: RMD) shares have fallen nearly 5% on Monday after initially spiking last week due to positive first-quarter financial results.
  • The company reported a 9% increase in revenue to US$1.3 billion last week and an 11% rise in net income to US$349 million, driven by heightened demand for sleep-focused medical devices.
  • Despite Friday's initial gains, investor sentiment turned negative over the weekend, affecting ResMed's US stocks and influencing ASX traders to reverse prior increases.

It's been a rather wild and woolly start to the trading week for the S&P/ASX 200 Index (ASX: XJO) this Monday so far. At the time of writing, the ASX 200 is down 0.17% after falling as much as 0.7% in morning trading earlier this session. But one ASX 200 stock is doing far worse than that. Let's discuss the current state of the ResMed Inc. (ASX: RMD) share price.

The ResMed share price is making the ASX's rough start to the week look pretty mild by comparison. This dual-listed healthcare stock ended last week at $39.53 a share. However, those same shares opened at just $37.85 this morning, before dropping to an intraday low of $37.58 soon after. That was a loss worth 4.93% at the time. The company is currently just a touch above that at the time of writing, down 4.2% at $37.87 a share.

So what's going on here?

A man wears a suit in reverse, so the shirt and jacket are on backwards.

Image source: Getty Images

Why is the ResMed share price down almost 5% today?

This dramatic share price drop appears to be a collective pullback from the spike in the company's stock last Friday, 31 October.

As we covered at the time, that initial spike followed a well-received (at least initially) first-quarter update from ResMed. This update revealed that the company increased its revenues by 9% to US$1.3 billion for the quarter. This was largely due to higher demand, particularly in the United States, Canada, and Latin America, for its sleep-focused medical devices and accessories.

ResMed also revealed that its gross margin rose 2.9% over the period, due to improved efficiencies in manufacturing and logistics.

Despite ResMed's expenses rising by 7% on a constant currency basis, the company reported an 11% rise in net income to US$349 million for the period. That translates to a diluted earnings per share (EPS) of US$2.37.

ResMed CEO and chair Mick Farrell told investors that the rest of the 2026 financial year looks bright for shareholders as well, flagging "strong, sustainable, profitable growth".

On Friday, ResMed shares rose by 1.65% by market close after soaring more than 2% higher at one point in intra-day trading. However, US investors had a less rosy reaction on Friday night (our time), sending the company's US stock 2.13% lower. It seems ASX investors have taken their cues from this today and are reversing Friday's gains accordingly. Let's see which sentiment takes hold over the rest of the trading week.

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

a doctor wearing a white coat with a stethoscope around her neck stares out a window with her hand to the side of her face as though in deep thought.
Healthcare Shares

Clarity Pharmaceuticals reports clinical trial milestones

Clarity Pharmaceuticals reported continued clinical progress for its prostate cancer imaging and therapy programs.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Healthcare Shares

Are Neuren Pharmaceuticals shares a buy, hold or sell after rocketing 16%?

This healthcare stock keeps rising.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Broker Notes

Up 64%, 3 reasons this expert predicts Pro Medicus shares will keep on giving

A leading expert forecasts more outperformance from the surging Pro Medicus share price.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Clarity Pharmaceuticals reports new SECuRE trial responses at higher dose

Clarity Pharmaceuticals reports further progress in its SECuRE prostate cancer trial, showing strong PSA responses and new complete responses at…

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Neuren Pharmaceuticals share price rockets: record Q2 DAYBUE sales and royalty upgrade

Second quarter net sales of DAYBUE increased 30%.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

Why this ASX healthcare stock is at the cusp of a 'Transformational Opportunity' – Expert

This ASX healthcare stock is one to watch.

Read more »

A woman leans forward with her hand behind her ear, as if trying to hear information.
ASX Share Market News

Earnings preview: can Cochlear shares rebound?

A decade low share price meets a make-or-break result.

Read more »

A female ASX investor looks through a magnifying glass that enlarges her eye and holds her hand to her face with her mouth open as if looking at something of great interest or surprise.
Healthcare Shares

Why I'm watching CSL shares like a hawk in August

A low valuation will look very different depending on what management says about the year ahead.

Read more »